Asahi Kasei pharmaceuticals business with $1B net revenue has two pharmaceutical companies, named Asahi Kasei Pharma (AKP) and Veloxis Pharmaceuticals. AKP is a mid-sized R&D-based Japanese company with strong presence in immunology, musculoskeletal, hematology and severe infections established through R&D and commercialization of our products in Asia. Veloxis is an US based company leading transplant area with an innovative product and ongoing development activities in that space in US and EU. Since Veloxis joined Asahi Kasei Group in 2020, AKP and Veloxis have an ambition to become one global specialty pharma to serve for our patients in immunology and transplant-related areas. For our future growth and to achieve our mission, we are collaborating closely and actively looking for opportunities from early to late stage in-licensing with global rights as well as M&A.